Navigation Links
Palatin Technologies Receives Non-Compliance Letter from NYSE Amex
Date:12/2/2010

of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about meeting continued listing standards, plans of compliance relating to regaining compliance with listing standards, future financings and other future expectations of Palatin Technologies, Inc., are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, availability of financing on acceptable terms, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, com
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
5. Palatin Technologies to Present at 8th Annual BIO Investor Forum
6. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
7. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
10. Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
11. Palatin Technologies to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
(Date:4/17/2014)... ward off depression among retirees, particularly among those who ... The Journals of Gerontology, Series B: Psychological Sciences ... Internet Use and Depression Among Retired Older Adults in ... report that Internet use reduced the probability of a ... , Late-life depression affects between 5 and 10 ...
(Date:4/17/2014)... general blood flow and alleviates muscle soreness after ... the University of Illinois at Chicago. , The ... the Archives of Physical Medicine and Rehabilitation ... in people who had not exercised, suggesting that ... level of physical activity. , Improved circulation and ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... HILL In 2006, University of North Carolina at Chapel ... levels of LDL cholesterol are more likely to have Parkinson,s ... study could not answer the question of whether low LDL ... were diagnosed with Parkinsons, or if they developed low LDL ...
... Program Will Put Home Medical Equipment Providers out of,Business ... Million Seniors and,Disabled People in Kansas City Area, ... program for durable medical equipment (DME) scheduled to be,implemented ... 1,2008, will put many DME providers out of business ...
... April 4, 2008 Most people assume,that cancer is ... Cancer Society, healthy behaviors could prevent approximately half,of cancer ... all based on the,latest research, which people can make ... at its earliest, most curable stages., -- Don,t ...
... they might want to avoid theft of Social Security checks ... finds that senior citizens in Baltimore seem to avoid visiting ... because they want to stay home and make sure no ... help doctors get a better handle on fluctuations in when ...
... April 4, 2008 -- A promising vaccine being tested ... do -- clear beta-amyloid plaques from the brain -- ... learning and memory abilities, according to a University of ... the predominant pathology of Alzheimer,s disease -- beta-amyloid plaques ...
... ward off gastroenteritis, which causes vomiting and diarrhea in children ... and Drug Administration has approved a second oral vaccine for ... diarrhea in infants and children. , The Rotarix vaccine is ... from 6 to 24 weeks of age. , ...
Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Medicare Bidding Program in Kansas City is Plagued by Problems, Says American Association for Homecare 2Health News:Medicare Bidding Program in Kansas City is Plagued by Problems, Says American Association for Homecare 3Health News:Ten Things You Can Do to Reduce Your Cancer Risk 2Health News:Ten Things You Can Do to Reduce Your Cancer Risk 3Health News:Ten Things You Can Do to Reduce Your Cancer Risk 4Health News:Ten Things You Can Do to Reduce Your Cancer Risk 5Health News:Seniors Avoid ER at Start of Month 2Health News:Seniors Avoid ER at Start of Month 3Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2Health News:FDA OKs New Rotavirus Vaccine 2Health News:FDA OKs New Rotavirus Vaccine 3
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
20 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box....
Angled, 20 gauge x 25 mm cannula with 30 gauge x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub, angled 45 degrees 2.5 mm from tip. 10 per box....
Medicine Products: